VYNE Therapeutics Inc (NASDAQ: VYNE) on Friday, plunged -5.36% from the previous trading day, before settling in for the closing price of $0.38. Within the past 52 weeks, VYNE’s price has moved between $0.34 and $4.30.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 65.87% annually for the last half of the decade. The company achieved an average annual earnings per share of 2.15%. With a float of $13.63 million, this company’s outstanding shares have now reached $15.96 million.
In an organization with 13 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 100.0%, operating margin of -7513.06%, and the pretax margin is -6969.42%.
VYNE Therapeutics Inc (VYNE) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of VYNE Therapeutics Inc is 18.19%, while institutional ownership is 36.93%. The most recent insider transaction that took place on Jan 15 ’25, was worth 43,800. In this transaction Director of this company bought 15,000 shares at a rate of $2.92, taking the stock ownership to the 51,472 shares.
VYNE Therapeutics Inc (VYNE) Latest Financial update
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.22 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.19) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.18% during the next five years compared to 65.87% growth over the previous five years of trading.
VYNE Therapeutics Inc (NASDAQ: VYNE) Trading Performance Indicators
VYNE Therapeutics Inc (VYNE) is currently performing well based on its current performance indicators. A quick ratio of 4.47 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.99, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.86 in one year’s time.
Technical Analysis of VYNE Therapeutics Inc (VYNE)
Let’s dig in a bit further. During the last 5-days, its volume was 3.85 million. That was better than the volume of 0.81 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 2.54%.
During the past 100 days, VYNE Therapeutics Inc’s (VYNE) raw stochastic average was set at 1.32%, which indicates a significant decrease from 1.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1002 in the past 14 days, which was lower than the 0.1326 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0684, while its 200-day Moving Average is $1.9920.
